Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesSpero Therapeutics Inc

Spero Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.005 USD -0.01 ( 1.47%)
Last update at 2026-11-12T15:44:00Z
VOLUME
92092
Market Cap
77.81M
P/E
3.28

Momentum Score

…

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.00
Low
1.03
High
52 Week Price Range
0.99
Low
1.89
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.02
Dividend Yield
-
Revenue TTM
110.98M
Revenue Per Share
2.10
Gross Profit TTM
-42.11M
Debt / Equity
0.05
ROE
29.06%
Net Debt
-70.79M
ROCE
-29.05%
Diluted EPS TTM
0.44

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -46.41M -89.76M -78.28M -60.92M -41.66M
Minority interest - - - - 0.35M
Net income -48.03M -91.30M -77.52M -60.17M -41.66M
Selling general administrative 36.48M 41.70M 21.44M 15.59M 12.89M
Gross profit 48.58M 18.26M 9.33M 4.74M 3.97M
Reconciled depreciation 0.87M 0.65M 0.76M 0.75M 0.41M
Ebit -42.20M -87.97M -79.87M -63.97M -43.22M
Ebitda -18.94M -87.37M -79.11M -63.22M -42.81M
Depreciation and amortization 23.26M 0.60M 0.76M 0.75M 0.41M
Non operating income net other - - 0.83M 2.29M 1.14M
Operating income -42.20M -87.97M -79.11M -63.22M -42.81M
Other operating expenses 79.15M 106.23M 88.44M 67.96M 42.81M
Interest expense 2.60M 1.94M 0.00M 0.00M 0.30M
Interest income 1.11M 0.35M 0.40M 1.33M 1.14M
Net interest income -1.50M -1.59M 0.40M 1.33M 1.14M
Income tax expense 1.61M 1.54M -0.76M -0.75M 1.14M
Total revenue 48.58M 18.26M 9.33M 4.74M 3.97M
Total operating expenses 79.15M 106.23M 88.44M 67.96M 42.81M
Cost of revenue - - - 65.78M 33.88M
Total other income expense net -4.22M -1.78M 0.83M 2.29M 1.14M
Net income from continuing ops -46.41M -89.76M -78.28M -60.92M -41.66M
Net income applicable to common shares -46.41M -89.76M -78.28M -60.92M -41.66M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 182.39M 124.80M 171.07M 153.45M 106.10M
Other current assets 4.18M 3.38M 8.83M 6.06M 4.82M
Total liab 75.50M 48.87M 82.78M 21.41M 31.53M
Total stockholder equity 106.89M 75.93M 88.29M 132.04M 74.57M
Other current liab 6.94M 8.97M 14.35M 12.24M 21.59M
Common stock 0.05M 0.05M 0.03M 0.03M 0.02M
Capital stock 0.05M 0.05M 0.04M 0.03M 0.02M
Retained earnings -391.07M -413.88M -367.46M -277.71M -199.43M
Other liab - 22.26M 58.14M 0.18M 0.25M
Other assets 0.00M 5.74M 5.64M 5.52M 3.54M
Cash 76.33M 109.11M 112.58M 85.21M 29.73M
Total current liabilities 37.15M 21.65M 18.67M 14.34M 26.66M
Current deferred revenue 27.11M 10.37M 1.86M - -
Net debt -70.79M -102.46M -105.25M -77.37M -24.18M
Short term debt 1.72M 1.69M 1.36M 0.95M 0.93M
Short long term debt total 5.54M 6.65M 7.33M 7.84M 5.54M
Other stockholder equity 497.91M 489.76M 455.72M 409.72M 273.97M
Property plant equipment - 5.49M 7.56M 1.67M 7.15M
Total current assets 131.21M 109.11M 157.87M 126.91M 82.05M
Net tangible assets - 75.93M 88.29M 132.04M 74.57M
Short term investments - 0.00M 33.82M 41.70M 52.31M
Net receivables 50.70M 1.08M 2.64M 6.18M 8.55M
Long term debt - - - 0.18M 0.25M
Inventory 0.00M -4.46M -0.36M -12.24M -13.37M
Accounts payable 1.38M 0.62M 1.10M 1.16M 4.15M
Accumulated other comprehensive income - - -0.00M -0.01M 0.02M
Common stock total equity - - - 0.03M 0.02M
Preferred stock total equity - - - 0.00M -
Retained earnings total equity - - - -277.71M -199.43M
Non currrent assets other 0.43M 10.20M 5.64M 17.76M 16.91M
Non current assets total 51.18M 15.70M 13.20M 26.55M 24.06M
Capital lease obligations 5.54M 6.65M 7.33M 7.84M 5.54M
Long term debt total - - - 0.18M 0.25M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 33.81M 7.67M 10.63M 29.84M -80.72M
Change to liabilities 21.41M 10.59M -12.18M 14.12M 3.66M
Total cashflows from investing activities 33.81M 7.67M 10.47M 29.53M -83.16M
Net borrowings -54.48M -54.48M -54.48M -54.48M -
Total cash from financing activities -29.55M 84.05M 130.88M 16.14M 69.52M
Change to operating activities -0.87M -1.56M -12.66M 13.30M -2.56M
Net income -46.41M -89.76M -78.28M -60.92M -41.66M
Change in cash -3.48M 27.38M 55.48M -4.35M -53.26M
Begin period cash flow 112.58M 85.21M 29.73M 34.08M 87.34M
End period cash flow 109.11M 112.58M 85.21M 29.73M 34.08M
Total cash from operating activities -7.73M -64.35M -85.87M -50.02M -39.62M
Issuance of capital stock 24.51M 35.37M 129.65M 15.79M 70.50M
Depreciation 0.87M 0.65M 0.76M 0.75M 0.41M
Other cashflows from investing activities - - - 29.84M -80.72M
Change to account receivables 1.20M 3.05M 2.43M -7.38M 0.64M
Sale purchase of stock 10.28M 27.54M 14.18M 16.14M 69.52M
Other cashflows from financing activities -64.34M 21.14M 52.22M 0.35M -0.98M
Change to netincome 15.73M 11.90M 4.56M 3.72M 3.37M
Capital expenditures 0.00M 0.04M 0.16M 0.31M 2.44M
Change receivables - - 2.18M -7.08M 1.41M
Cash flows other operating - - -2.88M 0.15M -6.13M
Cash and cash equivalents changes - - 55.48M -4.35M -53.26M
Change in working capital 22.09M 12.90M -13.39M 6.83M -1.07M
Stock based compensation 9.12M 9.43M 4.89M 3.78M 2.75M
Other non cash items 6.61M 2.37M 0.51M 0.36M -0.05M
Free cash flow -7.73M -64.31M -86.03M -50.33M -42.06M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SPRO
Spero Therapeutics Inc		 -0.01
1.47%		 1.00 3.28 - 0.85 0.83 0.18 0.69
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Spero Therapeutics Inc

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

675 Massachusetts Avenue, Cambridge, MA, United States, 02139

857 242 1600

https://sperotherapeutics.com

46

Name Title Year Born
Dr. Ankit Mahadevia M.D., MBA Co-Founder, Pres, CEO & Director 1981
Mr. Satyavrat Shukla C.F.A. CFO & Treasurer 1972
Ted Jenkins VP & Head of Investor Relations NA
Ms. Tamara Lynn Joseph L.L.M. Chief Legal Officer 1963
Mr. James P. Brady Chief Human Resource Officer NA
Mr. Timothy Keutzer Chief Devel. Officer 1968
Dr. Ian A. Critchley Head of Clinical Microbiology NA
Dr. Susannah Walpole Ph.D. Head of Clinical Operations NA
Dr. Angela Talley M.D. Sr. VP of Clinical Devel. NA
Dr. Kamal Hamed M.B.A., M.D., M.P.H. Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…